Early AVeNEW trial results were “quite compelling”

1119

Throwback to the 2019 Society of Interventional Radiology annual scientific meeting when Interventional News interviewed Bart Dolmatch (Mountain View, USA) on the early results of the AVeNEW trial – the first Level One trial dedicated solely to assess the safety and efficacy of the Covera (BD) covered stent designed to treat stenosis in the arteriovenous (AV) fistula access circuit. 

The early results were “quite compelling” says Dolmatch, who notes that a 71% treatment lesion primary patency was seen at six months, which he notes is a greater than 30% improvement compared to angioplasty alone. The data also shows that “not only are we doing better than angioplasty historically has done but also “much better than the original stent graft approved for this indication, he adds.  

Dolmatch also discusses some of the interesting developments in regard to vascular access and says that there is currently “a great amount of enthusiasm and excitement” for the use of catheter-based endovascular fistula creation.  

The interim findings of the AVeNEW trial were awarded Abstract of the Year at the Society of Interventional Radiology (SIR) 2020 Virtual Sessions (13–14 June). 

Subscribe to receive BLearning videos here: www.blearning.net/registration


LEAVE A REPLY

Please enter your comment!
Please enter your name here